Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Vaccines: 2023 Year in Review

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

Subscribe

Silas Inman is senior vice president of content at MJH Life Sciences.

Articles

Changes have been proposed to the quality payment program that could have ups and downs, but not, perhaps for some, until 2029.

CMS Proposes New Ophthalmology MVP, Shake Up for Cataract Surgery MIPS | AAO 2024

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024

Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery, shares the reasons why she chose to study metastatic breast cancer patients. 

Patient Advocacy Groups and Caretaker Diversity in Metastatic Breast Cancer Research 

There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.

Addressing the Challenges of AI is Imperative | AMCP Nexus 2024

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ID Week 2024

AMCP Nexus 2024

AHIP

AIDS Conference

ATS 

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Clinical

If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief. 

FDA Accepts NDA for Menopause Drug, Elinzanetant

Less than a quarter of menopausal women have their menopause symptoms entered into their charts at primary care visits, resulting in missed opportunities for timely treatment. 

Menopause Care Gaps Exist in Primary Care 

Insulin resistance reduction was seen in trials using both estrogen and estrogen plus progesterone, a meta-analysis of 17 studies reveal. 

Hormone Therapy Reduced Insulin Resistance in Postmenopausal Women, Study Shows

Insight into nocturnal hot flash timing could provide clues about heart disease risk in perimenopausal women. 

More Hot Flashes Occur in Second Half of Night, Preliminary Data Shows

Women with disadvantaged backgrounds may also benefit more than women with a higher socioeconomic status, study results show.

Postmenopausal Women Who Use Hormone Therapy Biologically Younger 

Women's Health

Latest News